Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
BAY-3827 (0-200 μM) has been shown to suppress AMPK kinase activity, with an IC50 value of 1.4 nM at low concentrations of 10 μM ATP and 15 nM at high concentrations of 2 mM ATP [1]. At 10 μM ATP concentration, BAY-3827 (0-200 μM) suppresses Flt3, c-Met, Rsk4, Aurora A, and IC50 values of 1324, 124, 788, and 36 nM, respectively [1]. Overnight administration of BAY-3827 significantly lowers the phosphorylation of ACC1 Ser79 in LNCaP and VCaP cells, and to a lesser degree in IMR-32, particularly Colo320 cells [1]. LNCaP and VCaP cells exhibit potent inhibitory effects when exposed to BAY-3827 (0–10 nM; 6 d) [1]. In cells implicated in the production of acylcarnitine in VCaP, BAY-3827 (1 and 5 μM; 24 and 48 hours) suppresses the expression of the LIPE gene, decreases the level of serine/threonine kinase AKT3, and limits the expression of numerous genes of the mitochondrial carnitine palmitoyltransferase (CPT) family [1]. In comparison to androgen-only treatment, BAY-3827 (5 μM; 2-4 d) significantly increases lipid droplet production [1].
|
---|---|
Cell Assay |
Cell proliferation assay[1]
Cell Types: LNCaP, VCaP, 22Rv1, C4-2B, PC-3 and DU-145 prostate cancer cell lines Tested Concentrations: 0-10 nM Incubation Duration: 6 d Experimental Results: For LNCaP and DU-145 prostate Cancer cell lines demonstrated strong inhibitory effects on VCaP cells, two prostate cancer cell lines, with IC50 values of 0.28 and 1.71 nM respectively. Inhibits 22Rv1 cell proliferation with an IC50 value of 5.55 nM. |
References |
[1]. Lemos C, et al. The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models. Cell Oncol (Dordr). 2021 Jun;44(3):581-594.
|
Molecular Formula |
C27H25FN6O
|
---|---|
Molecular Weight |
468.536
|
CAS # |
2377576-35-5
|
SMILES |
CCC1=CC=CC=C1C(NC2=NNC3=C(C)C(F)=C(C4C(C#N)=C(C)N(C)C(C)=C4C#N)C=C32)=O
|
InChi Key |
OZFFKOSQNBBYCA-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C27H25FN6O/c1-6-17-9-7-8-10-18(17)27(35)31-26-20-11-19(24(28)14(2)25(20)32-33-26)23-21(12-29)15(3)34(5)16(4)22(23)13-30/h7-11,23H,6H2,1-5H3,(H2,31,32,33,35)
|
Chemical Name |
N-(5-(3,5-dicyano-1,2,6-trimethyl-1,4-dihydropyridin-4-yl)-6-fluoro-7-methyl-1H-indazol-3-yl)-2-ethylbenzamide
|
Synonyms |
BAY3827 BAY-3827 BAY3827
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~25 mg/mL (~53.36 mM)
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1343 mL | 10.6714 mL | 21.3429 mL | |
5 mM | 0.4269 mL | 2.1343 mL | 4.2686 mL | |
10 mM | 0.2134 mL | 1.0671 mL | 2.1343 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.